TY - JOUR
T1 - Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019
T2 - a randomized, controlled trial
AU - Huygens, Sammy
AU - Hofsink, Quincy
AU - Nijhof, Inger S
AU - Goorhuis, Abraham
AU - Kater, Arnon P
AU - Te Boekhorst, Peter Aw
AU - Swaneveld, Francis
AU - Novotný, Věra Mj
AU - Bogers, Susanne
AU - Welkers, Matthijs Ra
AU - Papageorgiou, Grigorios
AU - Rijnders, Bart J
AU - Heijmans, Jarom
N1 - Funding Information: This work was funded by The Netherlands Organisation for Health Research and Development and an unrestricted grant from Sanquin Blood Supply Foundation. COVIG was provided by the Dutch Ministry of Public Health, Welfare, and Sport. Funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Funding to pay the Open Access publication charges for this article was provided by The Netherlands Organisation for Health Research and Development. Funding Information: Financial support. This work was funded by The Netherlands Organisation for Health Research and Development and an unrestricted grant from Sanquin Blood Supply Foundation. COVIG was provided by the Dutch Ministry of Public Health, Welfare, and Sport. Funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Funding to pay the Open Access publication charges for this article was provided by The Netherlands Organisation for Health Research and Development. Publisher Copyright: © 2022 The Author(s).
PY - 2023/1/15
Y1 - 2023/1/15
N2 - BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. RESULTS: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test). CONCLUSIONS: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.
AB - BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. RESULTS: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test). CONCLUSIONS: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.
KW - B-cell dysfunction
KW - COVID-19
KW - anti-SARS-CoV-2 hyperimmune globulin
KW - plasma-derived antibody therapy
KW - severely immunocompromised state
UR - http://www.scopus.com/inward/record.url?scp=85138789408&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/infdis/jiac334
DO - https://doi.org/10.1093/infdis/jiac334
M3 - Article
C2 - 35921542
SN - 0022-1899
VL - 227
SP - 206
EP - 210
JO - The Journal of Infectious Diseases
JF - The Journal of Infectious Diseases
IS - 2
ER -